Skip to content
thestock.space

Beryl Drugs (BSE: BERLDRG) had a P/E of 16.7× on 6 Nov 2026, below the industry P/E of 28.7×. Its ROCE of 8.7% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit fell 11% and 18% a year over 3 years. Debt is 0.25× equity. It is a small-cap company with a market cap of ₹13 Cr, ranked 146th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 6.4% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹24.99
Day high
₹26.00
Day low
₹23.97
Prev. close
₹25.00
Volume
2.4K

Health check

1 good · 1 fair · 4 to check
  • ReturnsBehind

    +6.4% over a year, better than 1 of 7 peers.

  • Price tagCheaper

    P/E 16.7 vs industry 28.7.

  • GrowthShrinking

    Sales −11.2%, profit −17.8% a year over 3 years.

  • ProfitabilityWeak

    ROCE 8.7% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.25× equity, interest covered 2.8×, Piotroski 4 of 9.

  • Red flags1 to check

    Return on equity is low at 4.4%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹13 Cr, #146 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹21 Cr · profit ₹1 Cr
Market cap
₹13 Cr
Small cap
P/E
16.7
Industry 28.7
Price to book
1.33
Peers 4.99
Dividend yield
0.00%
ROE
4.4%
Peers 14.7%
ROCE
8.7%
Peers 17.9%
Debt to equity
0.25
Debt ₹2.44 Cr
EPS (TTM)
₹1.55
OPM (TTM)
11.8%
Net margin 2.9%
Sales growth
+52.2%
Latest quarter vs a year ago
Profit growth
+946.4%
Latest quarter vs a year ago
Price to sales
0.62
EV/EBITDA 5.8

Strengths and risks

Strengths

  • Quarterly profit up 946.4% on a year ago.
  • Quarterly sales up 52.2% on a year ago.
  • P/E of 16.7 against an industry P/E of 28.7.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Return on equity is low at 4.4%.

Derived automatically from reported figures. Not a recommendation.

About Beryl Drugs

Beryl Drugs Limited engages in the manufacture and marketing of pharmaceutical products in India. It offers various branded and generic pharmaceutical formulations, bulk drugs, I.V. fluids, small volume injectables in liquid and dry powder forms, and eye and ear drops, as well as veterinary products. The company also provides research and development, and contract manufacturing services. It exports its products. The company was incorporated in 1993 and is…

Headquarters
Indore
Sector
Healthcare
ISIN
INE415H01017
Website
beryldrugs.com

Price range

52 weeks

₹15.92₹27.90

Today

₹23.97₹26.00
Avg volume (3M)
2.1K
1-year return
plus 6.4%
From 52-week high
minus 7.3%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
BERLDRGBeryl Drugs25.87plus 3.48%1316.71.338.7%4.4%11.8%−11.2%−17.8%0.00%plus 6.4%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
4.85.13.85.17.3
4.24.443.86.6
0.60.7−0.21.30.6
11.5%14.3%−5.2%26.1%8.9%
−00000
0.10.10.10.10.1
0.40.40.30.40.3
0.10.3−0.60.90.3
74.0%96.6%72.4%35.0%18.2%
00−0.20.60.2
0.040.02-0.021.110.44

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
−11.2%
Profit CAGR 3Y
−17.8%
EPS CAGR 3Y
−17.8%
ROE
4.4%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
26.726.420.918.7
–minus 0.9%minus 20.8%minus 10.8%
24.724.119.416.2
22.41.52.5
7.5%9.0%7.2%13.4%
0.20.41.40.1
0.40.40.50.3
0.81.21.31.5
−0−0.1−0.3−0.2
110.90.6
22.1%23.9%33.6%27.8%
0.80.80.60.4
–+0.3%minus 26.2%minus 25.1%
1.511.521.120.84

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
5.15.15.15.1
33.84.44.8
4.55.14.12.4
4.93.52.42.6
17.517.51615
5.8666.8
0.10.10.10.1
0.2–00
0.60.30.90.3
10.911.297.7
17.517.51615

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
2.40.83.33.6
−1.2−1.1−1−2.2
−1.20.1−1.6−2
0−0.20.7−0.5
−1.6−1.4−2.2−3.8
0.8−0.51.1−0.2

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you